Clinical Trials Logo

Asymptomatic Hyperuricemia clinical trials

View clinical trials related to Asymptomatic Hyperuricemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT05522504 Active, not recruiting - Gout Flare Clinical Trials

Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout

Start date: September 15, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate whether immune cells and their subtypes in peripheral blood affects the asymptomatic hyperuricemia, gout flare, intercritical gout and advanced gout.

NCT ID: NCT05406830 Recruiting - Clinical trials for Asymptomatic Hyperuricemia

Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia

Start date: July 13, 2022
Phase: N/A
Study type: Interventional

hyperuricemia (HUA) is an important risk factor for various chronic diseases, such as gout, and the current treatment programs for HUA are not ideal. It is urgent to find new methods to prevent and treat HUA and to carry out early clinical intervention. Acupuncture is commonly used for the treatment of HUA, while the evidence for its efficacy is still uncertain. This clinical trial aimed to evaluate the efficacy and safety of manual acupuncture for asymptomatic HUA.

NCT ID: NCT05302388 Completed - Clinical trials for Asymptomatic Hyperuricemia

A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

Start date: April 11, 2022
Phase: Phase 1
Study type: Interventional

The main purpose To evaluate the safety and tolerability of pegloticase in subjects with asymptomatic hyperuricemia by single intravenous infusion at different doses, and to provide a basis for multiple doses of Pegloticase in subjects with asymptomatic hyperuricemia. A secondary purpose To evaluate the pharmacokinetics, pharmacodynamics and immunogenicity of Pegloticase with single-pass intravenous drip in subjects with asymptomatic hyperuricemia. Exploratory purpose Plasma uricase activity (pUox) analysis of pegloticase with single-pass intravenous drip in subjects with asymptomatic hyperuricemia.

NCT ID: NCT03316131 Completed - Clinical trials for Asymptomatic Hyperuricemia

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Start date: October 25, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit

NCT ID: NCT03306758 Not yet recruiting - Gout Clinical Trials

The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

This study evaluate the serum uric acid lowering effect of sodium bicarbonate as well as its safety in patients with asymptomatic hyperuricemia or gout. Half of the participants will receive sodium bicarbonate only, while the other half receive none.